Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up
Presenter: Sibylle Loibl, Germany; Discussant: Javier Cortés, Spain
ESMO Virtual Plenary Resources
Monthly presentations of the latest, original scientific data from randomized phase III trials in oncology, or from phase II trials which demonstrate remarkable therapeutic benefit, scientific insight or progress in an area of unmet need.
The ESMO Virtual Plenaries are freely available to all healthcare professionals working in Oncology. Slides and webcasts from ESMO Virtual Plenaries are open to all, ESMO Members and free ESMO Account holders, according to the presenters' agreement to release them.
The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.
Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
Presenter: Philippe Moreau, France; Discussant: Francesca Gay, Italy
Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study
Presenter: Luis Paz-Ares, Spain; Discussant: Martin Reck, Germany
Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selinexor/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer
Presenter: Ignace Vergote, Belgium; Discussant: Amit Oza, Canada
Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
Presenter: Andrew Tutt, UK; Discussant: Mark Robson, USA